There are no individual reject rates established for each defect category that is classified as(D)(4) The reject rate established is cumulative for all (b)(4) defects.
Inspection Record
Cangene Corporation — FDA 483 Findings
View the regulator's official source The source document is always the basis for judgement.
Findings
Deviation 109218 was initiated on June 7, 2010 for HepaGamB Finished Goods lot (b)(4) having been EMPEYEE(S) SIGHATURE——Z
The firm’s deviation control system is inadequate in that it fails to adequately assess the classification of .
There is no defined change out period for product contact flexible hoses used in manufacturing.
The SOP for Growth Promotion of media used for’environmental monitoring is incomplete in that it does not specify the length oftime test articles should be incubated.
Not all lots ofproduct that fail the Acceptable Quality Limit (AQL) after the initial (B)(4) inspection is performed are reinspected under tightened limits for both the additional (6)(4) reinspection performed by production or the AQL performed by Quality.
Written procedures are not always followed.
SOP 25.026.0002.01.00 defines a On Oiled JO Ment A The printing, and circulation of such documents are not always controlled: A.
There is a lack of assurance that there is adequate control over critical documents including, but not limited to, Policies, Standard Operating Procedures (SOPs), Work Instructions (WIs) Forms, Electronic Templates (ETs) Drawingsand Manuals.
A record as of the US FDA document published on 2026-10-27. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.